LETTER to the EDITOR

Single Cell Analysis and Circulating Tumor Cells in Prostate
Cancer: Experience of an Observership at Cold Spring Harbor Laboratory, CSH and New York Presbyterian Hospital (Cornell Campus), New York TGF-β3, have been suggested to be strong predictors of metastatic prostate cancer (Chen et al., 2013) .
Accurate isolation/characterization of CTCs using high content single cell analysis holds tremendous prognostic and predictive therapeutic potential in prostate cancer management in both the American and Asian Indian patient cohorts. Indeed, single cell analyses/CTC enumeration provides novel therapeutic clinically-relevant intervention points/patient-centric opportunities for personalized treatments with targeted inhibitors in specific subsets of prostate cancer patients stratified according to Gleason score/prostate specific antigen level and tumor stage/metastasis.
Future clinical research targeting tumor-specific CTC subpopulations may be tremendously beneficial in the successful design/validation of cost-effective, sensitive and specific patient-centric predictive and prognostic biomarkers in human cancers, including prostate cancer, thereby reducing the increasing burden of cancers among ethnically disparate populations. 
